本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Soligenix, Inc.

1.60
+0.01000.63%
盤前1.640.0400+2.50%07:49 EST
成交量:37.00萬
成交額:59.56萬
市值:1,613.78萬
市盈率:-0.38
高:1.65
開:1.62
低:1.55
收:1.59
52周最高:6.23
52周最低:1.09
股本:1,008.61萬
流通股本:792.89萬
量比:1.06
換手率:4.67%
股息:- -
股息率:- -
每股收益(TTM):-4.2455
每股收益(LYR):-4.9786
淨資產收益率:-165.10%
總資產收益率:-69.38%
市淨率:2.12
市盈率(LYR):-0.32

資料載入中...

公司資料

公司名字:
Soligenix, Inc.
交易所:
NASDAQ
成立時間:
1987
員工人數:
15
公司地址:
29 Emmons Drive,Suite B-10,Princeton,New Jersey,United States
郵編:
08540
電話:
傳真:
609 452 6467
簡介:
Soligenix, Inc.成立於1987年,是一家臨床階段生物製藥公司,專註於開發產品,治療癌症和嚴重的胃腸道疾病的治療所產生的危及生命的副作用(仍然是一個未滿足的醫療需求),以及開發多種生物防禦疫苗和療法。

董事

名稱
職位
Christopher J. Schaber
Chairman of the Board and Chief Executive Officer and Director and President
Diane L. Parks
Director
Gregg A. Lapointe
Director
Jerome B. Zeldis
Director
Robert J. Rubin
Director

股東

名稱
職位
Christopher J. Schaber
Chairman of the Board and Chief Executive Officer and Director and President
Jonathan Guarino
Chief Financial Officer and Corporate Secretary and Senior Vice President
Oreola Donini
Chief Scientific Officer and Senior Vice President
Richard Straube
Chief Medical Officer